Literature DB >> 23715309

Febrile neutropenia in the tropics: a description of clinical and microbiological findings and their impact on inappropriate therapy currently used at an oncological reference center in Colombia.

Jorge A Cortés1, Sonia Cuervo, Carlos A Gómez, Diana Bermúdez, Teresa Martínez, Patricia Arroyo.   

Abstract

INTRODUCTION: Febrile neutropenia is a common complication of chemotherapy treatment of malignant hematological diseases. However, there is insufficient information regarding the infectious complications of febrile neutropenia in our country. Objective. We will evaluate the microbial characteristics of bacterial and fungal isolates and the clinical outcome of patients with febrile neutropenia who received medical attention at an oncological reference center in Colombia.
MATERIALS AND METHODS: A prospective case series included patients with histologically confirmed oncological disease, who were admitted because of febrile neutropenia or presented with febrile neutropenia during hospitalization. Patients with benign hematological diseases were excluded. Demographic, microbiological, and clinical features as well as treatment and outcome information from patients with febrile neutropenia were obtained. We performed univariate and multivariate analyses, with mortality defined as the outcome.
RESULTS: One hundred and thirty episodes of febrile neutropenia were identified in 104 patients. The mean patient age was 19, and 53% of the patients were male. Approximately 86% of the episodes occurred in patients with hematological disorders. An infectious site was identified in 65% of patients; 41% and 24% of the febrile neutropenia pateints´ episodes exhibited a localized infectious focus and developed bloodstream infections, respectively. The majority of infections were found in blood, urine, gastrointestinal tract, and soft tissue. Distribution analysis of microbiological isolates revealed 46.4% Gram-negative bacilli, 38.4% Gram-positive cocci, 8% fungi, and 7.1% parasites; there was a 7.7% mortality rate. Appropriate empirical antimicrobial therapy was a protection-related factor in multivariate analyses (OR= 0.17; 0.034 - 0.9 95% CI; p= 0.037).
CONCLUSIONS: The mortality rate was relatively low and comparable to the rate reported by developed countries. Inappropriate empirical antimicrobial therapy was the main factor associated with mortality.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23715309     DOI: 10.1590/S0120-41572013000100009

Source DB:  PubMed          Journal:  Biomedica        ISSN: 0120-4157            Impact factor:   0.935


  6 in total

Review 1.  Gastrointestinal and liver infections in children undergoing antineoplastic chemotherapy in the years 2000.

Authors:  Elio Castagnola; Eliana Ruberto; Alfredo Guarino
Journal:  World J Gastroenterol       Date:  2016-07-07       Impact factor: 5.742

2.  Emerging Anti-Microbial Resistance in Febrile Neutropenia: Is it high time to evaluate quality control measures?

Authors:  Uzma Mahar; Nida Anwar; Naveena Fatima; Jawad Hassan; Tahir Shamsi
Journal:  Pak J Med Sci       Date:  2020 Sep-Oct       Impact factor: 1.088

Review 3.  The current spectrum of infection in cancer patients with chemotherapy related neutropenia.

Authors:  Lior Nesher; Kenneth V I Rolston
Journal:  Infection       Date:  2013-08-23       Impact factor: 3.553

4.  Bloodstream infections in patients with malignancies: implications for antibiotic treatment in a Ghanaian tertiary setting.

Authors:  Noah Obeng-Nkrumah; Appiah-Korang Labi; Michael Ebo Acquah; Eric S Donkor
Journal:  BMC Res Notes       Date:  2015-12-01

5.  Management of Febrile Neutropenia: A Description of Clinical and Microbiological Findings by Focusing on Risk Factors and Pitfalls.

Authors:  Fatemeh Karimi; Farzaneh Ashrafi; Azadeh Moghaddas; Ali Derakhshandeh
Journal:  J Res Pharm Pract       Date:  2018 Jul-Sep

6.  Clinical Characteristics and Associated Factors of Mortality in Febrile Neutropenia Patients; a Cross Sectional Study.

Authors:  Hamidreza Hatamabadi; Ali Arhami Dolatabadi; Ayda Akhavan; Saeed Safari
Journal:  Arch Acad Emerg Med       Date:  2019-07-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.